# US 10,765,696 B2 · Compositions of and methods of treatment with zwitterionic polysaccharide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,765,696 B2
- Document ID: US10765696B2
- Status: Granted
- Kind: B2
- Application number: 15/580,624
- Filed: 2016-06-10
- Published: 2018-10-18
- Granted: 2020-09-08
- Earliest claimed: 2015-06-10
- Assignees: City of Hope; California Institute of Technology
- Applicants: City of Hope; California Institute of Technology
- Inventors: Edouard Cantin; Sarkis K. Mazmanian; Chandran Ramakrishna
- Web page: https://patentgrep.com/patent/US10765696B2

## CPC

- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 39/02: Bacterial antigens
- A61P 31/22: for herpes viruses
- C08B 37/006: {Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof}
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C12N 2710/16611: Simplexvirus, e.g. human herpesvirus 1, 2
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure includes compositions of a zwitterionic polysaccharide (e.g., B. fragilis capsular polysaccharide A (PSA)) (including active fragments thereof) and methods of treating viral infection and viral infection associated inflammation with compositions of a zwitterionic polysaccharide (e.g., B. fragilis capsular polysaccharide A (PSA)) (including active fragments thereof).

## Claims

### Claim 1

A method of treating a viral infection in a subject in need thereof, the method comprising administering to said subject an effective amount of a zwitterionic polysaccharide, wherein (i) the effective amount is effective to reduce neuroinflammation in the subject, and (ii) the zwitterionic polysaccharide is a zwitterionic bacterial polysaccharide or a zwitterionic capsular polysaccharide.

### Claim 2 (depends on 1)

The method of claim 1, wherein said zwitterionic polysaccharide is Bacteroides fragilis capsular polysaccharide A.

### Claim 3 (depends on 1)

The method of claim 1, wherein said method further comprises administering to said subject an effective amount of an anti-viral agent.

### Claim 4 (depends on 3)

The method of claim 3, wherein said anti-viral agent is aciclovir, amantadine, brincidovir, cidofovir, famciclovir, foscarnet, valaciclovir, penciclovir, ganciclovir, valganciclovir, lamivudin, zidovudin, emtricitabin, abacavir, tenofovir, didanosin, stavudin, efavirenz, enfuvirtide, enviroxime, nevirapin, amprenavir, indinavir, saquinavir, ritonavir, lopinavir, atazanavir, nelfinavir, oseltamivir, adefovir, lamivudine, ribavirin, interferon-alpha, pegylated interferon alpha, zanamivir, a pharmaceutically acceptable derivative of any one of the foregoing, or a combination of two or more thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein said viral infection is varicella-zoster virus infection, cytomegalovirus infection, Epstein-Barr virus infection, herpesvirus infection, West-Nile virus infection, polyomavirus infection, adenovirus infection, respiratory syncytial virus infection, norovirus infection, or influenza virus infection.

### Claim 6 (depends on 1)

The method of claim 1, wherein the viral infection is a neurotropic virus infection.

### Claim 7 (depends on 1)

The method of claim 1, wherein said zwitterionic polysaccharide is in an oral dosage form.

### Claim 8

A method of modulating an immune response in a subject in need thereof, the method comprising administering to said subject an effective amount of a zwitterionic polysaccharide and an effective amount of an anti-viral agent, wherein:
(a) the effective amount of the zwitterionic polysaccharide is effective to reduce neuroinflammation in the subject;
(b) the zwitterionic polysaccharide is a zwitterionic bacterial polysaccharide or a zwitterionic capsular polysaccharide; and
(c) said subject has a viral infection selected from the group consisting of: varicellazoster virus infection, cytomegalovirus infection, Epstein-Barr virus infection, herpesvirus infection, West-Nile virus infection, polyomavirus infection, adenovirus infection, respiratory syncytial virus infection, norovirus infection, and influenza virus infection.

### Claim 9 (depends on 8)

The method of claim 8, wherein said zwitterionic polysaccharide is Bacteroides fragilis capsular polysaccharide A.

### Claim 10 (depends on 8)

The method of claim 8, wherein said method activates B cells or T cells.

### Claim 11 (depends on 8)

The method of claim 8, wherein said method decreases inflammatory monocytes.

### Claim 12 (depends on 8)

The method of claim 8, wherein said anti-viral agent is selected from the group consisting of: aciclovir, amantadine, brincidovir, cidofovir, famciclovir, foscarnet, valaciclovir, penciclovir, ganciclovir, valganciclovir, lamivudin, zidovudin, emtricitabin, abacavir, tenofovir, didanosin, stavudin, efavirenz, enfuvirtide, enviroxime, nevirapin, amprenavir, indinavir, saquinavir, ritonavir, lopinavir, atazanavir, nelfinavir, oseltamivir, adefovir, lamivudine, ribavirin, interferon-alpha, pegylated interferon alpha, zanamivir, pharmaceutically acceptable derivative of any one of the foregoing, and a combination of two or more thereof.